Status:

COMPLETED

Trial Evaluating the Diagnostic Usefulness of Lumentin® 44 When Used as Contrast Agent

Lead Sponsor:

Lument AB

Collaborating Sponsors:

LINK Medical Research

Conditions:

Crohn Disease

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The trial is a phase 2 randomised, open, non-inferiority within patient-controlled multi-centre trial. Male and female subjects with a diagnosis of Crohn´s Disease and a clinical indication for an MR...

Detailed Description

The trial is a phase 2 randomised, open, non-inferiority within patient-controlled multi-centre trial. Patient recruitment will take place at 1 or more study centres by clinicians specialised in gast...

Eligibility Criteria

Inclusion

  • Subjects of either gender at least 18 years of age at time of signing the informed consent.
  • Subjects with a confirmed CD diagnosis
  • Clinical indication for an MRE examination of the small bowel, i.e. need for disease status evaluation due to, for example, a relapse/flare, disease status evaluation before starting a new treatment, evaluation of therapeutic effect of given treatment, change in symptomatology, follow-up of longstanding disease, and/or pre-operative mapping/investigation

Exclusion

  • Clinical suspicion of a severe general or an acute abdominal condition (i.e. bowel obstruction, bowel perforation, severe bleeding or severe inflammation), requiring acute or subacute management.
  • Moderate to severe dysphagia
  • Known allergy to egg albumin
  • Known severe retention of urine
  • Known cardiac arrythmia
  • Having untreated glaucoma
  • Having known manifest thyrotoxicosis
  • Having known phenylketonuria
  • Having known Glucose-6-phosphatase deficiency
  • Contraindicated IV administration of contrast media used in MRE or CTE
  • Known sensitivity to any of the components of the investigational product
  • Having metallic implants incompatible with MRI examination

Key Trial Info

Start Date :

January 29 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 12 2022

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT04321941

Start Date

January 29 2020

End Date

May 12 2022

Last Update

July 29 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of medical imaging and function

Malmo, Sweden, 20502

Trial Evaluating the Diagnostic Usefulness of Lumentin® 44 When Used as Contrast Agent | DecenTrialz